Sanofi Pasteur has announced that Dengvaxia dengue vaccine has now received its 11th marketing approval, four of which granted from Regulatory Authorities recognized by the World Health Organization (WHO).
To date the vaccine is approved in Mexico, The Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore.
The vaccine is also receiving endorsements from key medical societies at national and regional level. Notably, the Latin American Society for Pediatric Infectious Diseases (SLIPE for Sociedad Latino Americana de Infectología Pediátrica) just published its support for dengue vaccination. National medical societies in Indonesia, Brazil and Mexico have recently also recommended vaccination with Dengvaxia.
These recommendations are consistent with the World Health Organization position paper issued on July 29th recommending that countries with high burden of disease should consider introduction of Dengvaxia as part of an integrated dengue management program.
"We're pleased to see the growing medical and public health recognition for the vaccine," notes Su Peing Ng, MD, Head of Global Medical Affairs for Sanofi Pasteur. "With this new tool in hand, public health communities in dengue-endemic countries now have additional means to achieve the WHO objectives for 50% reduction in mortality and 25% reduction in morbidity due to dengue by 2020."